IASLC WORLD CONFERENCE

IASLC World Conference on Lung Cancer--Summary of the Presidential Symposium Research

Retrieved on: 
Tuesday, September 10, 2019
Cancer, Medicine, Health, Health effects of tobacco, Cancer screening, Lung cancer screening, Lung cancer, CT scan, National Lung Screening Trial, Cancer prevention

BARCELONA, Spain, Sept. 10, 2019 /PRNewswire/ --Note: This is a summary of research presented this morning at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer.

Key Points: 
  • BARCELONA, Spain, Sept. 10, 2019 /PRNewswire/ --Note: This is a summary of research presented this morning at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer.
  • A combination of the EarlyCDT-Lung Test followed by CT imaging in Scottish patients at risk for lung cancer resulted in a significant decrease in late-stage diagnosis of lung cancer and may decrease lung cancer mortality.
  • Lung cancer screening efforts have accelerated in the last decade, with researchers showing that low-dose CT screening is effective in reducing lung cancer mortality.
  • The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies.

IASLC World Conference on Lung Cancer--Summary of the Presidential Symposium Research

Retrieved on: 
Monday, September 9, 2019
Cancer, Medicine, Health, Health effects of tobacco, Cancer screening, Lung cancer screening, Lung cancer, CT scan, National Lung Screening Trial, Cancer prevention

BARCELONA, Spain, Sept. 9, 2019 /PRNewswire/ -- Note:This is a summary of research presented this morning at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer.

Key Points: 
  • BARCELONA, Spain, Sept. 9, 2019 /PRNewswire/ -- Note:This is a summary of research presented this morning at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer.
  • A combination of the EarlyCDT-Lung Test followed by CT imaging in Scottish patients at risk for lung cancer resulted in a significant decrease in late-stage diagnosis of lung cancer and may decrease lung cancer mortality.
  • Lung cancer screening efforts have accelerated in the last decade, with researchers showing that low-dose CT screening is effective in reducing lung cancer mortality.
  • The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies.

IASLC World Conference on Lung Cancer--Summary of the Presidential Symposium Research

Retrieved on: 
Monday, September 9, 2019
Cancer, Medicine, Health, Health effects of tobacco, Cancer screening, Lung cancer screening, Lung cancer, CT scan, National Lung Screening Trial, Cancer prevention

BARCELONA, Spain, Sept. 9, 2019 /PRNewswire/ -- Note:This is a summary of research presented this morning at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer.

Key Points: 
  • BARCELONA, Spain, Sept. 9, 2019 /PRNewswire/ -- Note:This is a summary of research presented this morning at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer.
  • A combination of the EarlyCDT-Lung Test followed by CT imaging in Scottish patients at risk for lung cancer resulted in a significant decrease in late-stage diagnosis of lung cancer and may decrease lung cancer mortality.
  • Lung cancer screening efforts have accelerated in the last decade, with researchers showing that low-dose CT screening is effective in reducing lung cancer mortality.
  • The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies.

IASLC World Conference on Lung Cancer--Press Briefing Summary from Sunday, September 8th

Retrieved on: 
Sunday, September 8, 2019
Lung cancer, Neoplasms, Non-small-cell lung carcinoma, KRAS, Adenocarcinoma of the lung, Clinical medicine, Cancer, Treatment of lung cancer

There were no dose-limiting toxicities and no adverse events leading to discontinuation in the 34 NSCLC patients enrolled.

Key Points: 
  • There were no dose-limiting toxicities and no adverse events leading to discontinuation in the 34 NSCLC patients enrolled.
  • Of the 34 patients, only nine (26.5 percent) reported treatment-related adverse events of grade one or two.
  • "KRAS G12C mutant lung adenocarcinoma is one of the largest subsets of NSCLC potentially amenable to targeted therapies.
  • The announcement was made at the International Association for the Study of Lung Cancer World Conference on Lung Cancer in Barcelona, Spain by JTO editor Dr. Alex Adjei.

IASLC World Conference on Lung Cancer--Press Briefing Summary from Sunday, September 8th

Retrieved on: 
Sunday, September 8, 2019
Clinical medicine, Medicine, Non-small-cell lung carcinoma, Lung cancer, KRAS, Adenocarcinoma of the lung, Targeted therapy, Health, Treatment of lung cancer

Note: This is a summary of research presented this morning at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer.

Key Points: 
  • Note: This is a summary of research presented this morning at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer.
  • There were no dose-limiting toxicities and no adverse events leading to discontinuation in the 34 NSCLC patients enrolled.
  • "KRAS G12C mutant lung adenocarcinoma is one of the largest subsets of NSCLC potentially amenable to targeted therapies.
  • The announcement was made at the International Association for the Study of Lung Cancer World Conference on Lung Cancer in Barcelona, Spain by JTO editor Dr. Alex Adjei.